Abeona therapeutics reports third quarter 2022 financial results

Following positive topline data from phase 3 viital™ study of eb-101 with both co-primary endpoints met, abeona plans to submit bla to u.s. fda in 2q 2023
ABEO Ratings Summary
ABEO Quant Ranking